| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Journal of Thoracic and Cardiovascular Surgery, Vol 116, 716-730, Copyright © 1998 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association
NOTE: Fulltext is available only in pdf format
EL Alderman, JH Levy, JB Rich, M Nili, B Vidne, H Schaff, G Uretzky, G Pettersson, JJ Thiis, CB Hantler, B Chaitman and A Nadel
OBJECTIVE: We examined the effects of aprotinin on graft patency,
prevalence of myocardial infarction, and blood loss in patients undergoing
primary coronary surgery with cardiopulmonary bypass. METHODS: Patients
from 13 international sites were randomized to receive intraoperative
aprotinin (n = 436) or placebo (n = 434). Graft angiography was obtained a
mean of 10.8 days after the operation. Electrocardiograms, cardiac enzymes,
and blood loss and replacement were evaluated. RESULTS: In 796 assessable
patients, aprotinin reduced thoracic drainage volume by 43% (P < .0001)
and requirement for red blood cell administration by 49% (P < .0001).
Among 703 patients with assessable saphenous vein grafts, occlusions
occurred in 15.4% of aprotinin-treated patients and 10.9% of patients
receiving placebo (P = .03). After we had adjusted for risk factors
associated with vein graft occlusion, the aprotinin versus placebo risk
ratio decreased from 1.7 to 1.05 (90% confidence interval, 0.6 to 1.8).
These factors included female gender, lack of prior aspirin therapy, small
and poor distal vessel quality, and possibly use of aprotinin-treated blood
as excised vein perfusate. At United States sites, patients had
characteristics more favorable for graft patency, and occlusions occurred
in 9.4% of the aprotinin group and 9.5% of the placebo group (P = .72). At
Danish and Israeli sites, where patients had more adverse characteristics,
occlusions occurred in 23.0% of aprotinin- and 12.4% of placebo-treated
patients (P = .01). Aprotinin did not affect the occurrence of myocardial
infarction (aprotinin: 2.9%; placebo: 3.8%) or mortality (aprotinin: 1.4%;
placebo: 1.6%). CONCLUSIONS: In this study, the probability of early vein
graft occlusion was increased by aprotinin, but this outcome was promoted
by multiple risk factors for graft occlusion.
ARTICLES
Analyses of coronary graft patency after aprotinin use: results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial
Division of Cardiovascular Medicine, Stanford University Medical Center, Calif 94305, USA.
This article has been cited by other articles:
|
|
 |
|
  J. J. Jokinen, K. Werkkala, T. Vainikka, T. Perakyla, J. Simpanen, and L. Ihlberg Clinical value of intra-operative transit-time flow measurement for coronary artery bypass grafting: a prospective angiography-controlled study Eur J Cardiothorac Surg, June 1, 2011; 39(6): 918 - 923. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Du, J. Zhou, J. Tang, Q. An, K. Lin, X. Wu, K. Tao, and J. Liu Aprotinin combined with nitric oxide and prostaglandin E1 protects the canine kidney from cardiopulmonary bypass-induced injury, Eur J Cardiothorac Surg, July 1, 2010; 38(1): 98 - 103. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Szabo, G. Veres, T. Radovits, H. Haider, N. Krieger, S. Bahrle, C. Miesel-Groschel, S. Niklisch, M. Karck, and A. van de Locht Effects of novel synthetic serine protease inhibitors on postoperative blood loss, coagulation parameters, and vascular relaxation after cardiac surgery J. Thorac. Cardiovasc. Surg., January 1, 2010; 139(1): 181 - 188. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. E. Greilich, M. E. Jessen, N. Satyanarayana, C. W. Whitten, G. A. Nuttall, J. M. Beckham, M. H. Wall, and J. F. Butterworth The Effect of Epsilon-Aminocaproic Acid and Aprotinin on Fibrinolysis and Blood Loss in Patients Undergoing Primary, Isolated Coronary Artery Bypass Surgery: A Randomized, Double-Blind, Placebo-Controlled, Noninferiority Trial Anesth. Analg., July 1, 2009; 109(1): 15 - 24. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Petaja, M. Salmenpera, K. Pulkki, and V. Pettila Biochemical Injury Markers and Mortality After Coronary Artery Bypass Grafting: A Systematic Review Ann. Thorac. Surg., June 1, 2009; 87(6): 1981 - 1992. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-H. Yap, N. Andrianopoulos, D. T. Dinh, B. Billah, A. Rosalion, J. A. Smith, G. C. Shardey, P. D. Skillington, J. Tatoulis, M. Mohajeri, et al. Short- and midterm outcomes of coronary artery bypass surgery performed by surgeons in training J. Thorac. Cardiovasc. Surg., May 1, 2009; 137(5): 1088 - 1092. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. R. McIlroy, P. S. Myles, L. E. Phillips, and J. A. Smith Antifibrinolytics in cardiac surgical patients receiving aspirin: a systematic review and meta-analysis Br. J. Anaesth., February 1, 2009; 102(2): 168 - 178. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Henry MBChB, P. Carless BHSc MMedS, D. Fergusson PhD MHA, and A. Laupacis MD MSc The safety of aprotinin and lysine-derived antifibrinolytic drugs in cardiac surgery: a meta-analysis Can. Med. Assoc. J., January 20, 2009; 180(2): 183 - 193. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Grant, Z. Kon, A. Joshi, E. Christenson, S. Kallam, N. Burris, J. Gu, and R. S. Poston Is Aprotinin Safe to Use in a Cohort at Increased Risk for Thrombotic Events: Results From a Randomized, Prospective Trial in Off-Pump Coronary Artery Bypass Ann. Thorac. Surg., September 1, 2008; 86(3): 815 - 822. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Dunning, M. Versteegh, A. Fabbri, A. Pavie, P. Kolh, U. Lockowandt, S. A. M. Nashef, and on behalf of the EACTS Audit and Guidelines Commit Guideline on antiplatelet and anticoagulation management in cardiac surgery Eur J Cardiothorac Surg, July 1, 2008; 34(1): 73 - 92. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. B. Bittner, J. Lemke, M. Lange, A. Rastan, and F. W. Mohr The Impact of Aprotinin on Blood Loss and Blood Transfusion in Off-Pump Coronary Artery Bypass Grafting Ann. Thorac. Surg., May 1, 2008; 85(5): 1662 - 1668. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Sundt The demise of aprotinin: Our share of the blame. J. Thorac. Cardiovasc. Surg., April 1, 2008; 135(4): 729 - 731. [Full Text] [PDF]
|
|
|
|
|
|
M. P. Eaton Antifibrinolytic Therapy in Surgery for Congenital Heart Disease Anesth. Analg., April 1, 2008; 106(4): 1087 - 1100. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Westaby Aprotinin: Twenty-five years of claim and counterclaim J. Thorac. Cardiovasc. Surg., March 1, 2008; 135(3): 487 - 491. [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Levy, K. A. Tanaka, and J. M. Bailey Cardiac Surgical Pharmacology , January 1, 2008; 3(2008): 77 - 110. [Full Text]
|
|
|
|
|
|
P. J. Van der Linden, J.-F. Hardy, A. Daper, A. Trenchant, and S. G. De Hert Cardiac surgery with cardiopulmonary bypass: does aprotinin affect outcome? Br. J. Anaesth., November 1, 2007; 99(5): 646 - 652. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. McEvoy, S. T. Reeves, J. G. Reves, and F. G. Spinale Aprotinin in Cardiac Surgery: A Review of Conventional and Novel Mechanisms of Action Anesth. Analg., October 1, 2007; 105(4): 949 - 962. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Maddali and M. C. Rajakumar Tranexamic Acid and Primary Coronary Artery Bypass Surgery: A Prospective Study Asian Cardiovascular and Thoracic Annals, August 1, 2007; 15(4): 313 - 319. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Veres, T. Radovits, H. Schultz, L.-n. Lin, J. Hutter, E. Weigang, Z. Szabolcs, and G. Szabo Effect of recombinant aprotinin on postoperative blood loss and coronary vascular function in a canine model of cardiopulmonary bypass Eur J Cardiothorac Surg, August 1, 2007; 32(2): 340 - 345. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. R. Bridges Valid Comparisons of Antifibrinolytic Agents Used in Cardiac Surgery Circulation, June 5, 2007; 115(22): 2790 - 2792. [Full Text] [PDF]
|
|
|
|
|
|
J. R. Brown, N. J.O. Birkmeyer, and G. T. O'Connor Meta-Analysis Comparing the Effectiveness and Adverse Outcomes of Antifibrinolytic Agents in Cardiac Surgery Circulation, June 5, 2007; 115(22): 2801 - 2813. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. I. Coleman, V. T. Rigali, J. Hammond, J. Kluger, K. W. Jeleniowski, and C. M. White Evaluating the safety implications of aprotinin use: The Retrospective Evaluation of Aprotinin in Cardio Thoracic Surgery (REACTS) J. Thorac. Cardiovasc. Surg., June 1, 2007; 133(6): 1547 - 1552. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ronald and J. Dunning Does use of aprotinin decrease the incidence of stroke and neurological complications in adult patients undergoing cardiac surgery? Interact CardioVasc Thorac Surg, December 1, 2006; 5(6): 767 - 773. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. C. Body and C. D. Mazer Pro: Aprotinin Has a Good Efficacy and Safety Profile Relative to Other Alternatives for Prevention of Bleeding in Cardiac Surgery Anesth. Analg., December 1, 2006; 103(6): 1354 - 1359. [Full Text] [PDF]
|
|
|
|
|
|
D. Royston, J. H. Levy, J. Fitch, W. Dietrich, S. C. Body, J. M. Murkin, B. D. Spiess, and A. Nadel Full-Dose Aprotinin Use in Coronary Artery Bypass Graft Surgery: An Analysis of Perioperative Pharmacotherapy and Patient Outcomes Anesth. Analg., November 1, 2006; 103(5): 1082 - 1088. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. D. Desai, S. Miwa, D. Kodama, T. Koyama, G. Cohen, M. P. Pelletier, E. A. Cohen, G. T. Christakis, B. S. Goldman, and S. E. Fremes A randomized comparison of intraoperative indocyanine green angiography and transit-time flow measurement to detect technical errors in coronary bypass grafts J. Thorac. Cardiovasc. Surg., September 1, 2006; 132(3): 585 - 594. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Riha, J. A. Hubacek, R. Poledne, P. Kellovsky, A. Brezina, and J. Pirk IL-10 and TNF-{beta} gene polymorphisms have no major influence on lactate levels after cardiac surgery Eur J Cardiothorac Surg, July 1, 2006; 30(1): 54 - 58. [Full Text] [PDF]
|
|
|
|
|
|
J. Jaggers and J. H. Lawson Coagulopathy and Inflammation in Neonatal Heart Surgery: Mechanisms and Strategies Ann. Thorac. Surg., June 1, 2006; 81(6): S2360 - S2366. [Full Text] [PDF]
|
|
|
|
|
|
J. R. Cooper Jr, J. Abrams, O.H. Frazier, R. Radovancevic, B. Radovancevic, A. W. Bracey, M. J. Kindo, and I. D. Gregoric Fatal pulmonary microthrombi during surgical therapy for end-stage heart failure: Possible association with antifibrinolytic therapy J. Thorac. Cardiovasc. Surg., May 1, 2006; 131(5): 963 - 968. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. G. Raja and G. D. Dreyfus Modulation of Systemic Inflammatory Response after Cardiac Surgery Asian Cardiovascular and Thoracic Annals, December 1, 2005; 13(4): 382 - 395. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Vanek, M. Jares, R. Fajt, Z. Straka, K. Jirasek, M. Kolesar, P. Brucek, and M. Maly Fibrinolytic inhibitors in off-pump coronary surgery: a prospective, randomized, double-blind TAP study (tranexamic acid, aprotinin, placebo) Eur J Cardiothorac Surg, October 1, 2005; 28(4): 563 - 568. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Engles Review and application of serine protease inhibition in coronary artery bypass graft surgery Am. J. Health Syst. Pharm., September 15, 2005; 62(18_Supplement_4): S9 - S14. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Levy Overview of clinical efficacy and safety of pharmacologic strategies for blood conservation Am. J. Health Syst. Pharm., September 15, 2005; 62(18_Supplement_4): S15 - S19. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Lindvall, U. Sartipy, and J. van der Linden Aprotinin Reduces Bleeding and Blood Product Use in Patients Treated With Clopidogrel Before Coronary Artery Bypass Grafting Ann. Thorac. Surg., September 1, 2005; 80(3): 922 - 927. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. van der Linden, G. Lindvall, and U. Sartipy Aprotinin Decreases Postoperative Bleeding and Number of Transfusions in Patients on Clopidogrel Undergoing Coronary Artery Bypass Graft Surgery: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial Circulation, August 30, 2005; 112(9_suppl): I-276 - I-280. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Karski, G. Djaiani, J. Carroll, M. Iwanochko, P. Seneviratne, P. Liu, W. Kucharczyk, L. Fedorko, T. David, and D. Cheng Tranexamic acid and early saphenous vein graft patency in conventional coronary artery bypass graft surgery: A prospective randomized controlled clinical trial J. Thorac. Cardiovasc. Surg., August 1, 2005; 130(2): 309 - 314. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. K. Tempe Reducing allogeneic transfusion in cardiac surgery Br. J. Anaesth., August 1, 2005; 95(2): 277 - 278. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Fergusson, K. C. Glass, B. Hutton, and S. Shapiro Randomized controlled trials of aprotinin in cardiac surgery: could clinical equipoise have stopped the bleeding? Clinical Trials, June 1, 2005; 2(3): 218 - 232. [Abstract] [PDF]
|
|
|
|
|
|
V. Shrivastava and E. Akowuah Impact of clopidogrel in coronary artery bypass grafting Eur J Cardiothorac Surg, January 1, 2005; 27(1): 176 - 177. [Full Text] [PDF]
|
|
|
|
|
|
A. M. Mahdy and N. R. Webster Perioperative systemic haemostatic agents Br. J. Anaesth., December 1, 2004; 93(6): 842 - 858. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Sedrakyan, T. Treasure, and J. A. Elefteriades Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: A systematic review and meta-analysis of randomized clinical trials J. Thorac. Cardiovasc. Surg., September 1, 2004; 128(3): 442 - 448. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. S. Donahue Factor V Leiden and Perioperative Risk Anesth. Analg., June 1, 2004; 98(6): 1623 - 1634. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kalkat, A. Levine, and J. Dunning Does use of aprotinin in coronary artery bypass graft surgery affect graft patency? Interact CardioVasc Thorac Surg, March 1, 2004; 3(1): 124 - 128. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. K. Smith, S. K. Datta, L. H. Muhlbaier, G. Samsa, A. Nadel, and J. Lipscomb Cost analysis of aprotinin for coronary artery bypass patients: analysis of the randomized trials Ann. Thorac. Surg., February 1, 2004; 77(2): 635 - 642. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. L. Mickleborough, S. Carson, and J. Ivanov Gender differences in quality of distal vessels: effect on results of coronary artery bypass grafting J. Thorac. Cardiovasc. Surg., October 1, 2003; 126(4): 950 - 958. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. P. Taggart, V. Djapardy, M. Naik, and A. Davies A randomized trial of aprotinin (Trasylol) on blood loss, blood product requirement, and myocardial injury in total arterial grafting J. Thorac. Cardiovasc. Surg., October 1, 2003; 126(4): 1087 - 1094. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Karski and J. T. Balatbat Blood Conservation Strategies in Cardiac Surgery Seminars in Cardiothoracic and Vascular Anesthesia, June 1, 2003; 7(2): 175 - 188. [Abstract] [PDF]
|
|
|
|
|
|
Y. Deng, K. Byth, and H. S. Paterson Age and Left Ventricular Impairment Predict Reopening for Bleeding Asian Cardiovascular and Thoracic Annals, June 1, 2003; 11(2): 147 - 152. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Levy and K. A. Tanaka Inflammatory response to cardiopulmonary bypass Ann. Thorac. Surg., February 1, 2003; 75(2): S715 - S720. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Bailey, K. A. Tanaka, and J. H. Levy Cardiac Surgical Pharmacology , January 1, 2003; 2(2003): 85 - 118. [Full Text]
|
|
|
|
 |
|
 F. Isgro, O. Stanisch, A.-H Kiessling, S. Gurler, P. Hellstern, and W. Saggau Topical application of aprotinin in cardiac surgery Perfusion, September 1, 2002; 17(5): 347 - 351. [Abstract] [PDF]
|
|
|
|
|
|
C. M. Samama, O. Langeron, N. Rosencher, X. Capdevila, P. Rouche, M. Pegoix, J. Berniere, and P. Coriat Aprotinin Versus Placebo in Major Orthopedic Surgery: A Randomized, Double-Blinded, Dose-Ranging Study Anesth. Analg., August 1, 2002; 95(2): 287 - 293. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. A. Nuttall, D. N. Fass, L. J. Oyen, W. C. Oliver Jr., and M. H. Ereth A Study of a Weight-Adjusted Aprotinin Dosing Schedule During Cardiac Surgery Anesth. Analg., February 1, 2002; 94(2): 283 - 289. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Murkin, J. Maurer, and S. Niemcryk Full dose aprotinin administration is associated with a significant decrease in perioperative stroke in patients undergoing elective cardiac surgery: a meta-analysis Ann. Thorac. Surg., January 1, 2002; 73(1): S374 - 374. [Full Text] [PDF]
|
|
|
|
|
|
R. C. Landis, G. Asimakopoulos, M. Poullis, D. O. Haskard, and K. M. Taylor The antithrombotic and antiinflammatory mechanisms of action of aprotinin Ann. Thorac. Surg., December 1, 2001; 72(6): 2169 - 2175. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Murkin Adverse Central Nervous System Outcomes After Cardiopulmonary Bypass: A Beneficial Effect of Aprotinin? Seminars in Cardiothoracic and Vascular Anesthesia, November 1, 2001; 5(4): 282 - 285. [Abstract] [PDF]
|
|
|
|
|
|
R. C. Landis, D. O. Haskard, and K. M. Taylor New antiinflammatory and platelet-preserving effects of aprotinin Ann. Thorac. Surg., November 1, 2001; 72(5): S1808 - S1813. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Levy Pharmacologic preservation of the hemostatic system during cardiac surgery Ann. Thorac. Surg., November 1, 2001; 72(5): S1814 - S1820. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Despotis, M. S. Avidan, and C. W. Hogue Jr Mechanisms and attenuation of hemostatic activation during extracorporeal circulation Ann. Thorac. Surg., November 1, 2001; 72(5): S1821 - S1831. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Murkin Attenuation of neurologic injury during cardiac surgery Ann. Thorac. Surg., November 1, 2001; 72(5): S1838 - S1844. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kottke-Marchant and S. Sapatnekar Hemostatic Abnormalities in Cardiopulmonary Bypass: Pathophysiologic and Transfusion Considerations Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2001; 5(3): 187 - 206. [Abstract] [PDF]
|
|
|
|
|
|
J. M. Alvarez, L. R. Jackson, C. Chatwin, and J. J. Smolich Low-dose postoperative aprotinin reduces mediastinal drainage and blood product use in patients undergoing primary coronary artery bypass grafting who are taking aspirin: A prospective, randomized, double-blind, placebo-controlled trial J. Thorac. Cardiovasc. Surg., September 1, 2001; 122(3): 457 - 463. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Poullis, R C Landis, and K M Taylor Aprotinin: is it prothrombotic? Perfusion, September 1, 2001; 16(5): 401 - 409. [Abstract] [PDF]
|
|
|
|
|
|
M. J. Ray, M. M. Hales, L. Brown, M. F. O'Brien, and E. G. Stafford Postoperatively administered aprotinin or epsilon aminocaproic acid after cardiopulmonary bypass has limited benefit Ann. Thorac. Surg., August 1, 2001; 72(2): 521 - 526. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. F. Del Rizzo, M. C. Moon, J. P. Werner, and P. Zahradka A novel organ culture method to study intimal hyperplasia at the site of a coronary artery bypass anastomosis Ann. Thorac. Surg., April 1, 2001; 71(4): 1273 - 1279. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Ray and M. F. O'Brien Comparison of epsilon aminocaproic acid and low-dose aprotinin in cardiopulmonary bypass: efficiency, safety and cost Ann. Thorac. Surg., March 1, 2001; 71(3): 838 - 843. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Casati, D. Guzzon, M. Oppizzi, F. Bellotti, A. Franco, C. Gerli, M. Cossolini, G. Torri, G. Calori, S. Benussi, et al. Tranexamic acid compared with high-dose aprotinin in primary elective heart operations: Effects on perioperative bleeding and allogeneic transfusions J. Thorac. Cardiovasc. Surg., September 1, 2000; 120(3): 520 - 527. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Poullis, R. Manning, M. Laffan, D. O. Haskard, K. M. Taylor, and R. C. Landis The antithrombotic effect of aprotinin: actions mediated via the proteaseactivated receptor 1 J. Thorac. Cardiovasc. Surg., August 1, 2000; 120(2): 370 - 378. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Levy Platelet inhibitors and bleeding in cardiac surgical patients Ann. Thorac. Surg., August 1, 2000; 70(2): S9 - 11. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Beath, G. A. Nuttall, D. N. Fass, W. C. Oliver Jr., M. H. Ereth, and L. J. Oyen Plasma Aprotinin Concentrations During Cardiac Surgery: Full- Versus Half-Dose Regimens Anesth. Analg., August 1, 2000; 91(2): 257 - 264. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. H. Edmunds Jr The quill passes Ann. Thorac. Surg., July 1, 2000; 70(1): 1 - 2. [Full Text] [PDF]
|
|
|
|
|
|
B. I. Wong, R. F. McLean, S. E. Fremes, K. A. Deemar, E. M. Harrington, G. T. Christakis, and B. S. Goldman Aprotinin and tranexamic acid for high transfusion risk cardiac surgery Ann. Thorac. Surg., March 1, 2000; 69(3): 808 - 816. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. De Bonis, F. Cavaliere, F. Alessandrini, E. Lapenna, F. Santarelli, U. Moscato, R. Schiavello, and G. F. Possati TOPICAL USE OF TRANEXAMIC ACID IN CORONARY ARTERY BYPASS OPERATIONS: A DOUBLE-BLIND, PROSPECTIVE, RANDOMIZED, PLACEBO-CONTROLLED STUDY J. Thorac. Cardiovasc. Surg., March 1, 2000; 119(3): 575 - 580. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. B. Berger, E. L. Alderman, A. Nadel, and H. V. Schaff Frequency of Early Occlusion and Stenosis in a Left Internal Mammary Artery to Left Anterior Descending Artery Bypass Graft After Surgery Through a Median Sternotomy on Conventional Bypass : Benchmark for Minimally Invasive Direct Coronary Artery Bypass Circulation, December 7, 1999; 100(23): 2353 - 2358. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Graham and H. O’Kane Is a high hematocrit value an independent risk factor for adverse outcome after coronary artery bypass grafting? J. Thorac. Cardiovasc. Surg., October 1, 1999; 118(4): 765 - 765. [Full Text]
|
|
|
|
|
|
M. Hendrikx, H. Jiang, H. Gutermann, J. Toelsie, D. Renard, A. Briers, J. L. Pauwels, and U. Mees RELEASE OF CARDIAC TROPONIN I IN ANTEGRADE CRYSTALLOID VERSUS COLD BLOOD CARDIOPLEGIA J. Thorac. Cardiovasc. Surg., September 1, 1999; 118(3): 452 - 459. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Damiano The minimally invasive direct coronary artery bypass procedure: What is its future role? J. Thorac. Cardiovasc. Surg., July 1, 1999; 118(1): 207 - 208. [Full Text]
|
|
|
|
 |
|
 Aprotinin During Coronary Revascularization: Friend or Foe? Journal Watch Cardiology, December 11, 1998; 1998(1211): 9 - 9. [Full Text]
|
|
|
|
 |
|
 GW Dec and GW Dec Aprotinin During Coronary Revascularization: Friend or Foe? Journal Watch, January 1, 1998; 1998(0): JC199812110000009 - JC199812110000009. [Abstract] [Full Text]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
